MacroGenics Inc
NASDAQ:MGNX

Watchlist Manager
MacroGenics Inc Logo
MacroGenics Inc
NASDAQ:MGNX
Watchlist
Price: 1.37 USD -0.72% Market Closed
Market Cap: 86.7m USD

MacroGenics Inc
Operating Expenses

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

MacroGenics Inc
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
MacroGenics Inc
NASDAQ:MGNX
Operating Expenses
-$173.6m
CAGR 3-Years
15%
CAGR 5-Years
7%
CAGR 10-Years
-5%
Abbvie Inc
NYSE:ABBV
Operating Expenses
-$22.7B
CAGR 3-Years
-2%
CAGR 5-Years
-8%
CAGR 10-Years
-7%
Gilead Sciences Inc
NASDAQ:GILD
Operating Expenses
-$11.6B
CAGR 3-Years
-2%
CAGR 5-Years
-3%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Operating Expenses
-$13.8B
CAGR 3-Years
-12%
CAGR 5-Years
-7%
CAGR 10-Years
-4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Expenses
-$5.6B
CAGR 3-Years
-18%
CAGR 5-Years
-16%
CAGR 10-Years
-16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Expenses
-$8.4B
CAGR 3-Years
-17%
CAGR 5-Years
-16%
CAGR 10-Years
-14%
No Stocks Found

MacroGenics Inc
Glance View

Market Cap
86.7m USD
Industry
Biotechnology

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The company is headquartered in Rockville, Maryland and currently employs 427 full-time employees. The company went IPO on 2013-10-10. The company is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is MGC018, an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. The company is also developing enoblituzumab, an Fc-optimized monoclonal antibody (mAb) that targets B7-H3 and molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system's response to cancer. Its clinical pipeline includes two bispecific DART product candidates that co-engage both PD-1 and lymphocyte-activation gene 3 (LAG-3) (tebotelimab), and PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (lorigerlimab). In addition, it is also developing MGD024.

MGNX Intrinsic Value
1.87 USD
Undervaluation 27%
Intrinsic Value
Price

See Also

What is MacroGenics Inc's Operating Expenses?
Operating Expenses
-173.6m USD

Based on the financial report for Sep 30, 2025, MacroGenics Inc's Operating Expenses amounts to -173.6m USD.

What is MacroGenics Inc's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-5%

Over the last year, the Operating Expenses growth was 28%. The average annual Operating Expenses growth rates for MacroGenics Inc have been 15% over the past three years , 7% over the past five years , and -5% over the past ten years .

Back to Top